Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop

Leuk Lymphoma. 2018 Oct;59(10):2305-2317. doi: 10.1080/10428194.2018.1427858. Epub 2018 Feb 2.


Predicated on our improved understanding of the disease biology, we have seen remarkable advances in the management of multiple myeloma over the past few years. Recently approved drugs have radically transformed the treatment paradigm and improved survivals of myeloma patients. The progress has necessitated revision of the diagnostic criteria, risk-stratification and response definition. The huge disparities in economy, healthcare infrastructure and access to novel drugs among different Asian countries will hinder the delivery of optimum myeloma care to patients managed in resource-constrained environments. In the light of the tremendous recent changes and evolution in myeloma management, it is timely that the resource-stratified guidelines from the Asian Myeloma Network be revised to provide updated recommendations for Asia physicians practicing under various healthcare reimbursement systems. This review will highlight the most recent advances and our recommendations on how they could be integrated in both resource-abundant and resource-constrained facilities.

Keywords: Myeloma; novel agents; resource-stratified.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use
  • Asia
  • Consensus
  • Consensus Development Conferences as Topic
  • Drug Resistance, Neoplasm
  • Health Care Rationing / methods
  • Health Care Rationing / standards*
  • Health Care Rationing / trends
  • Health Services Accessibility / economics
  • Health Services Accessibility / trends
  • Healthcare Disparities / economics
  • Healthcare Disparities / trends
  • Humans
  • International Cooperation*
  • Medical Oncology / methods
  • Medical Oncology / standards*
  • Medical Oncology / trends
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / economics
  • Multiple Myeloma / therapy*
  • Neoplasm Recurrence, Local / diagnosis
  • Neoplasm Recurrence, Local / economics
  • Neoplasm Recurrence, Local / therapy*
  • Practice Guidelines as Topic
  • Risk Assessment
  • Stem Cell Transplantation / economics
  • Stem Cell Transplantation / standards


  • Antineoplastic Agents